Kadcyla (ado-trastuzumab emtansine) – a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer is approved by US FDA. Breast cancer is the second leading cause of cancer-related death among women. Almost 20 percent of breast cancers have increased amounts of the HER2 protein.
HER2 is a protein involved in normal cell growth. It is found in increased amounts on some types of cancer cells (HER2-positive), including some breast cancers. In these HER2-positive breast cancers, the increased amount of the HER2 protein contributes to cancer cell growth and survival.
Kadcyla is intended for patients who were previously treated with trastuzumab, another anti-HER2 therapy, and taxanes, a class of chemotherapy drugs commonly used for the treatment of breast cancer.
?Kadcyla is trastuzumab connected to a drug called DM1 that interferes with cancer cell growth,? said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA?s Center for Drug Evaluation and Research. ?Kadcyla delivers the drug to the cancer site to shrink the tumor, slow disease progression and prolong survival. It is the fourth approved drug that targets the HER2 protein.?
Referred to as T-DM1 during clinical research, Kadcyla was reviewed under the FDA?s priority review program, which provides for an expedited six-month review of drugs that may provide safe and effective therapy when no satisfactory alternative therapy exists, or offer significant improvement compared to marketed products.
Kadcyla is being approved with a Boxed Warning alerting patients and health care professionals that the drug can cause liver toxicity, heart toxicity and death. The drug can also cause severe life-threatening birth defects, and pregnancy status should be verified prior to starting Kadcyla treatment.
The most common side effects reported in patients treated with Kadcyla were nausea, fatigue, pain in the muscles or joints, low levels of platelets in the blood (thrombocytopenia), increased levels of liver enzymes, headache, and constipation.
Source: U.S. Food and Drug Administration, USA